Robert E. Landry - Oct 14, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Oct 14, 2022
Transactions value $
-$541,258
Form type
4
Date filed
10/18/2022, 04:06 PM
Previous filing
Apr 11, 2022
Next filing
Nov 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $573K +1.5K +5.22% $381.92 30.2K Oct 14, 2022 Direct F1
transaction REGN Common Stock Tax liability -$849K -1.14K -3.78% $743.78 29.1K Oct 14, 2022 Direct F1
transaction REGN Common Stock Sale -$265K -358 -1.23% $739.50 28.7K Oct 17, 2022 Direct F1
holding REGN Common Stock 250 Oct 14, 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.5K -11.72% $0.00 11.3K Oct 14, 2022 Common Stock 1.5K $381.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.